Aurobindo Pharma Limited (NSE:AUROPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 610.07B |
| Revenue (ttm) | 320.25B |
| Net Income (ttm) | 33.91B |
| Shares Out | 580.80M |
| EPS (ttm) | 58.32 |
| PE Ratio | 18.01 |
| Forward PE | 15.70 |
| Dividend | 8.00 (0.76%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 1,872,840 |
| Average Volume | 1,494,704 |
| Open | 1,048.00 |
| Previous Close | 1,041.00 |
| Day's Range | 1,036.50 - 1,056.60 |
| 52-Week Range | 1,010.00 - 1,592.00 |
| Beta | 0.13 |
| RSI | 38.59 |
| Earnings Date | Aug 14, 2025 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretrovira... [Read more]
Financial Performance
In 2024, Aurobindo Pharma's revenue was 317.24 billion, an increase of 9.39% compared to the previous year's 290.02 billion. Earnings were 34.86 billion, an increase of 9.86%.
Financial StatementsNews
Aurobindo Pharma denies media reports on $5.5 billion Zentiva buyout
Aurobindo Pharma Limited has issued an official clarification regarding media reports suggesting that the company is closing in on a potential $5.5 billion acquisition of Zentiva. The clarification, f...
Pharma sector stocks in focus: Citi flags competitive setback for Dr Reddy’s, Aurobindo in iron sucrose opportunity
Citi has highlighted a potential setback for Indian generic drugmakers Dr Reddy’s Laboratories and Aurobindo Pharma after the USFDA approved two generic versions of Iron Sucrose, developed by Viatris ...
Raymond to Dr Reddy's: Textiles, pharma stocks bear tariffs brunt
Following US President Trump's tariff announcement, Indian pharmaceutical and textile companies experienced significant stock declines. Gokaldas Exports saw the steepest fall at 15.9%, with other text...
Aurobindo Pharma share: Macquarie downgrades to underperform, flags US business concerns
Macquarie has retained an ‘Underperform’ rating on Aurobindo Pharma with a target price of ₹1,010, citing a weak Q1FY26 performance and rising concerns over growth in the US market. The stock currentl...
Aurobindo Pharma board declares interim dividend of Rs 4 per share for FY26
Aurobindo Pharma has announced a significant interim dividend of 400%, translating to ₹4.00 per equity share of face value ₹1 each. The decision was approved during the Board of Directors meeting held...
Top Q1 results today, August 4: Shree Cements, Aurobindo Pharma, DLF, Marico, Godfrey Phillips and more to announce earnings
A busy earnings day is lined up for Monday, August 4, 2025, with over 190 listed companies scheduled to release their financial results for the first quarter of FY26. The announcements span across mul...
Amid Trump tariff fears, Aurobindo strikes biggest deal; To acquire Lannett for Rs 2185 crore
Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is making its largest acquisitio.
Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching
Aurobindo Pharma shares slip nearly 3% after Macquarie downgrades stock, cuts target price to Rs 1,010
Aurobindo Pharma shares were under pressure in early trade, falling close to 3% after brokerage firm Macquarie issued a double downgrade on the stock. The firm revised its rating to ‘underperform’ fro...
Top stocks in focus on July 3: Nestle India, Aurobindo Pharma, Hindustan Zinc, V2 Retail, CSB Bank and more
Indian benchmark indices ended lower on Wednesday, July 2. The NSE Nifty 50 declined by 88 points or 0.35% to settle at 25,453.40, while the BSE Sensex dropped 287.60 points or 0.34%, closing at 83,40...
Aurobindo Pharma’s subsidiary CuraTeQ Biologics secures marketing approval for trastuzumab biosimilar ‘Dazublys’
Aurobindo Pharma’s wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has achieved a major milestone with the European Commission granting marketing authorization for Dazublys™, its trastuzu...
Aurobindo Pharma’s CuraTeQ secures UK’s MHRA approval for Dyrupeg
CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for...
Nuvama bullish on Aurobindo Pharma, sees 15% profit CAGR through FY27
Nuvama Institutional Equities has reiterated a ‘Buy’ call on Aurobindo Pharma, with a target price of ₹1,460, as it sees the stock poised for a strong recovery led by new product launches, capacity ex...
Pharma stocks in focus as Trump announces tariffs on sector ‘soon’
Indian pharmaceutical stocks are in focus today after U.S. President Donald Trump announced that pharma tariffs are coming very soon. According to industry data, companies with the highest U.S. revenu...
Aurobindo Pharma's US arm incorporates new subsidiary called Cresedemo Pharma
HYDERABAD: Aurobindo Pharma on Monday informed the bourses that its wholly-owned US subsidiary, Aurobindo Pharma USA Inc, has incorporated a wholly-ow.
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
In May, the U.S. District Court for the District of Delaware ruled in favor of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) regarding its ‘721 formulation patent for Nuplazid (pimavanserin), Acadia’s d...
Top stocks to buy today: Stock recommendations for May 30, 2025
Stock market recommendations: Bajaj Broking Research suggests a resilient Indian equity market, projecting Nifty consolidation between 24,400-25,200 with a bullish outlook supported by rate cut expect...
Aurobindo Pharma shares fall over 2% after Citi maintains ‘Sell’ rating, cuts target price to Rs 1,100
Aurobindo Pharma shares fell over 2% after Citi maintained a ‘Sell’ rating and lowered its target price to ₹1,100. Citi expressed concerns about flattening growth in the US market and rising margin pr...
Motilal Oswal retains ‘Buy’ on Aurobindo Pharma, sets target at Rs 1,370 on strong EU presence, growth visibility
Motilal Oswal has maintained a Buy rating on Aurobindo Pharma with a target price of ₹1,370, citing strong Q4 performance, recovery in production, and growth traction in European markets. The brokerag...
Nuvama cuts Aurobindo Pharma target to Rs 1,485 but retains ‘Buy’ on healthy EBITDA margin
Nuvama Institutional Equities has retained its Buy rating on Aurobindo Pharma (ARBP) but revised its target price down to ₹1,485 from ₹1,677, citing a mixed Q4 performance and a cautious FY26 outlook....
Stocks to watch today on May 28: LIC, Aurobindo Pharma, Info Edge among top brokerage picks
Brokerage firms have released fresh research notes on key Indian stocks post Q4FY25 earnings. Life Insurance Corporation of India (LIC), Aurobindo Pharma, and Info Edge are among the most discussed, w...
CLSA trims FY26-27 estimates for Aurobindo Pharma after Pen-G plant disruption
CLSA has reiterated its ‘Outperform’ rating on Aurobindo Pharma, with a target price of ₹1,400, following its highest-ever revenue and EBITDA performance in Q4FY25. Revenue rose to ₹8,382 crore, while...
HSBC advises to Buy Aurobindo Pharma, says long-term outlook intact despite EBITDA miss
HSBC has maintained a ‘Buy’ rating on Aurobindo Pharma, setting a target price of ₹1,415. The company posted an in-line revenue performance in Q4FY25 but missed on EBITDA due to higher-than-expected o...
Goldman Sachs retains ‘Buy’ on Aurobindo Pharma, sees value in stock despite gRevlimid headwinds
Goldman Sachs has reaffirmed its ‘Buy’ call on Aurobindo Pharma with a target price of ₹1,275, viewing the Q4FY25 results as decent despite upcoming challenges. Revenue came in at ₹8,382 crore, up 10....
Citi maintains ‘Sell’ on Aurobindo Pharma after Q4 results, trims earnings estimates on margin risks post gRevlimid
Citi has maintained a ‘Sell’ rating on Aurobindo Pharma and cut its target price to ₹1,100, flagging concerns around flattening growth in the US market and rising margin risks in the coming quarters. ...